Tissue Plasminogen Activator for Acute Ischemic Stroke

Comprehensive Summary

The NINDS trial evaluates whether intravenous tissue plasminogen activator (t-PA), when administered within three hours of acute ischemic stroke onset, can improve neurologic and functional outcomes. The researchers conducted a randomized, double-blind, placebo effect controlled trial in two parts. This trial had 624 patients. Part one focused on early neurologic improvement at 24 hours, and this was measured by ≥ 4 point decrease in the NIH stroke scale. Part two evaluated the long-term outcomes at three months using four validated metrics. These metrics included, the Barthel INdex, modified Rankin Scale (mRS), Glasgow Outcome Scale (GOS), and the NIH Stroke Scale. Even though part one showed no significant difference at 24 hours, the long-term results were not the same. At three months, the patients treated with t-PA showed a 30 % relative increase in the likelihood of achieving minimal or no disability, changing into an 11-13 % absolute improvement on major functional scales. The global odds ratio for a favorable outcome was 1.7 (95% CI, 1.2-2.6; p = 0.008). This benefit came despite a higher rate of symptomatic intracerebral hemorrhage (6.4 % w/ t-PA and 0.6 % w/ placebo) in the span of 36 hours. However, the mortality didn’t increase with treatment (17 % w/ t-PA and 2 % w/ placebo; p = 0.30). The benefit is tightly linked to extremely early treatment.

Outcomes and Implications

This trial was the first to demonstrate that an acute treatment could truly improve recovery after an ischemic stroke, and it became the foundation for all kinds of modern stroke care. This study showed that rapid reperfusion within a three hour window can substantially increase the chance of returning to independent function. This helped shift stroke from an untreatable condition to a great medical emergency requiring mobilization similar to myocardial infarction care. Although t-PA comes with a measurable bleeding risk, the trial shows that with strict blood pressure control, careful patient selection, and rapid imaging can benefit functional independence.